Creo Medical Group (LON:CREO) Announces Quarterly Earnings Results

Creo Medical Group (LON:CREO) announced its earnings results on Wednesday. The company reported GBX (2) earnings per share for the quarter, Digital Look Earnings reports. Creo Medical Group had a negative net margin of 268.57% and a negative return on equity of 38.29%.

Creo Medical Group Price Performance

Shares of LON:CREO opened at GBX 9.80 on Friday. The company has a 50 day moving average price of GBX 12.62 and a two-hundred day moving average price of GBX 12.82. The company has a debt-to-equity ratio of 8.09, a quick ratio of 2.19 and a current ratio of 2.79. The company has a market capitalization of £47.61 million, a PE ratio of 9.80 and a beta of 1.56. Creo Medical Group has a 52 week low of GBX 9.50 and a 52 week high of GBX 18.50.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reiterated a “house stock” rating and set a GBX 40 target price on shares of Creo Medical Group in a research report on Thursday, July 23rd.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.